---
title: "Iovance Biotherapeutics updates corporate presentation, reiterates $350M–$370M FY26 guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291590413.md"
description: "Iovance Biotherapeutics updated its corporate presentation and reiterated FY2026 revenue guidance of $350M–$370M, with Q2 guidance at $86M–$88M. The company reported a cash position of ~$319M as of March 31, 2026, providing runway into 2028. Key highlights include a commercial footprint of over 90 treatment centers and ~1,500 patients treated with TIL products, alongside pipeline updates for melanoma and NSCLC programs."
datetime: "2026-07-02T21:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291590413.md)
  - [en](https://longbridge.com/en/news/291590413.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291590413.md)
generator: "portal-rs"
---

# Iovance Biotherapeutics updates corporate presentation, reiterates $350M–$370M FY26 guidance

**Iovance Biotherapeutics updated its corporate presentation and reiterated FY2026 revenue guidance of $350M–$370M and Q2 guidance of $86M–$88M.**

**Key Highlights:**

-   Company updated corporate presentation used for healthcare conferences, analysts and stockholders; Exhibit 99.1 attached to 8-K.
-   Reiterated FY2026 revenue guidance of $350M–$370M and Q2 2026 guidance of $86M–$88M.
-   Reported cash position of ~$319M as of March 31, 2026, with runway into 2028.
-   Highlighted commercial footprint: >90 Authorized Treatment Centers and ~1,500+ patients treated with TIL products.
-   Outlined pipeline and commercial plans including frontline melanoma registrational TILVANCE-301 and fast-track NSCLC lifileucel programs.

Original SEC Filing: IOVANCE BIOTHERAPEUTICS, INC. \[ IOVA \] - 8-K - Jul. 02, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)

## Related News & Research

- [IOVA: Strong sales growth, expanding clinical pipeline, and operational efficiencies support long-term outlook](https://longbridge.com/en/news/298626037.md)
- [Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance?](https://longbridge.com/en/news/295324260.md)
- [CervoMed neflamapimod Phase 2a nfvPPA biomarker data set for ISFTD 2026 oral session](https://longbridge.com/en/news/298589195.md)
- [Immunocore reaches 540-patient enrollment target in Phase 3 TEBE-AM trial of Kimmtrak in advanced melanoma](https://longbridge.com/en/news/298907550.md)
- [Precise Biometrics Sets Terms and Opens Exercise Period for 2026 Warrants](https://longbridge.com/en/news/298686788.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**